Open AccessModelling the risk-benefit impact of H1N1 influenza vaccines
Author(s) -
Lawrence D. Phillips,
Barbara Fasolo,
N. Zafiropoulous,
Hans Georg Eichler,
Falk Ehmann,
Veronika Jekerle,
Piotr Kramarz,
A Nicoll,
Thomas Lönngren
Publication year - 2013
Publication title -
european journal of public health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 91
eISSN - 1464-360X
pISSN - 1101-1262
DOI - 10.1093/eurpub/ckt006
Subject(s) - deliberation , weighting , pandemic , medicine , decision tree , decision analysis , risk assessment , decision aids , operations research , actuarial science , disease , covid-19 , infectious disease (medical specialty) , computer science , statistics , business , alternative medicine , data mining , computer security , political science , mathematics , pathology , radiology , politics , law
Shortly after the H1N1 influenza virus reached pandemic status in June 2009, the benefit-risk project team at the European Medicines Agency recognized this presented a research opportunity for testing the usefulness of a decision analysis model in deliberations about approving vaccines soon based on limited data or waiting for more data. Undertaken purely as a research exercise, the model was not connected to the ongoing assessment by the European Medicines Agency, which approved the H1N1 vaccines on 25 September 2009.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom